Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of sn-38 to ovarian cancer

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2425-2434

  Vangara, Kiran Kumar ^a   Liu, Jingbo Louise ^b   Palakurthi, Srinath ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b TEXAS A AND M UNIVERSITY KINGSVILLE   (United States)

Author keywords

CD44 targeted delivery; CTAB assay; Hyaluronic acid; Ovarian cancer; PLGA nanoparticles; SN 38; Surface decoration

Indexed keywords

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CETRIMIDE; FIRTECAN; HERMES ANTIGEN; HYALURONIC ACID; MACROGOL; NANOPARTICLE; POLYGLACTIN; SOLVENT; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; DRUG CARRIER; DRUG DERIVATIVE; IRINOTECAN; MACROGOL DERIVATIVE; POLY(LACTIC GLYCOLIC ACID) POLY(ETHYLENEGLYCOL) COPOLYMER; POLY(LACTIC-GLYCOLIC ACID)-POLY(ETHYLENEGLYCOL) COPOLYMER;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG STABILITY; DRUG TARGETING; EMULSION; EVAPORATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; NANOENCAPSULATION; NONHUMAN; OVARY CANCER; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL; ANIMAL; CD44-TARGETED DELIVERY; CHEMISTRY; CHO CELL; CTAB ASSAY; HAMSTER; METABOLISM; OVARY TUMOR; PLGA NANOPARTICLES; SN-38; SURFACE DECORATION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

CD44-TARGETED DELIVERY; CTAB ASSAY; HYALURONIC ACID; OVARIAN CANCER; PLGA NANOPARTICLES; SN-38; SURFACE DECORATION;

ANIMALS; ANTIGENS, CD44; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; DRUG CARRIERS; EMULSIONS; FEMALE; HUMANS; HYALURONIC ACID; NANOPARTICLES; OVARIAN NEOPLASMS; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; TOPOISOMERASE I INHIBITORS;

MLCS; MLOWN;

EID: 84881333043     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Kalogera E, Dowdy SC, Mariani A, Aletti G, Bakkum-Gamez JN and Cliby WA: Utility of closed suction pelvic drains at time of large bowel resection for ovarian cancer. Gynecol Oncol 126: 391-396, 2012.
2. Siegel R, Naishadham D, and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
3. Agarwal R and Kaye SB: Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516, 2003.
4. Palakurthi S, Yellepeddi VK and Vangara KK: Recent trends in cancer drug resistance reversal strategies using nanoparticles. Expert Opin Drug Deliv 9: 287-301, 2012.
5. Yellepeddi VK, Kumar A, Maher DM, Chauhan SC, Vangara KK and Palakurthi S: Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT. Anticancer Res 31: 897-906, 2011.
6. Yellepeddi VK, Kumar A and Palakurthi S: Biotinylated poly(amido)amine (PAMAM) dendrimers as carriers for drug delivery to ovarian cancer cells in vitro. Anticancer Res 29: 2933-2943, 2009.
7. Ossipov DA: Nanostructured hyaluronic acid-based materials for active delivery to cancer. Expert Opin Drug Deliv 7: 681-703, 2010.
8. Toole BP: Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4: 528-539, 2004.
9. Orian-Rousseau V: CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46: 1271-1277, 2010.
10. Prud'homme GJ: Cancer stem cells and novel targets for antitumor strategies. Curr Pharm Des 18: 2838-2849, 2012.
11. Ghosh SC, Neslihan Alpay S and Klostergaard J: CD44: a validated target for improved delivery of cancer therapeutics. Expert Opin Ther Targets 16: 635-650, 2012.
12. Platt VM and Szoka FC Jr.: Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 5: 474-486, 2008.
13. Toole BP, Wight TN and Tammi MI: Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem 277: 4593-4596, 2002.
14. Nair HB, Huffman S, Veerapaneni P, Kirma NB, Binkley P, Perla RP, Evans DB and Tekmal RR: Hyaluronic acid-bound letrozole nanoparticles restore sensitivity to letrozole-resistant xenograft tumors in mice. J Nanosci Nanotechnol 11: 3789-3799, 2011.
15. Eliaz RE and Szoka FC Jr.: Liposome-encapsulated doxorubicin targeted to CD44: A strategy to kill CD44-overexpressing tumor cells. Cancer Res 61: 2592-2601, 2001.
16. Park K, Lee MY, Kim KS and Hahn SK: Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate. Biomaterials 31: 5258-5265, 2010.
17. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A and Preat V: PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161: 505-522, 2012.
18. Yadav AK, Mishra P, Mishra AK, Jain S and Agrawal GP: Development and characterization of hyaluronic acid-Anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine 3: 246-257, 2007.
19. Yadav AK, Agarwal A, Rai G, Mishra P, Jain S, Mishra AK, Agrawal H and Agrawal GP: Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil. Drug Deliv 17: 561-572, 2010.
20. Zhao H, Rubio B, Sapra P, Wu D, Reddy P, Sai P, Martinez A, Gao Y, Lozanguiez Y, Longley C, Greenberger LM and Horak ID: Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. Bioconjug Chem 19: 849-859, 2008.
21. Ebrahimnejad P, Dinarvand R, Sajadi A, Jaafari MR, Nomani AR, Azizi E, Rad-Malekshahi M and Atyabi F: Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines. Nanomedicine 6: 478-485, 2010.
22. Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S and Ahmad I: Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm 270: 93-107, 2004.
23. Roger E, Lagarce F and Benoit JP: Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration. Eur J Pharm Biopharm 79: 181-188, 2011.
24. Boddu SH, Jwala J, Chowdhury MR and Mitra AK: In vitro evaluation of a targeted and sustained release system for retinoblastoma cells using Doxorubicin as a model drug. J Ocul Pharmacol Ther 26: 459-468, 2010.
25. Qhattal HS and Liu X: Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronangrafted liposomes. Mol Pharm 8: 1233-1246, 2011.
26. Jwala J, Boddu SH, Shah S, Sirimulla S, Pal D and Mitra AK: Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir. J Ocul Pharmacol Ther 27: 163-172, 2011.
27. Xuan T, Zhang JA and Ahmad I: HPLC method for determination of SN-38 content and SN-38 entrapment efficiency in a novel liposome-based formulation, LE-SN38. J Pharm Biomed Anal 41: 582-588, 2006.
28. Jokerst JV, Lobovkina T, Zare RN and Gambhir SS: Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 6: 715-728, 2011.
29. Shen JM, Gao FY, Yin T, Zhang HX, Ma M, Yang YJ and Yue F: cRGD-functionalized polymeric magnetic nanoparticles as a dual-drug delivery system for safe targeted cancer therapy. Pharmacological research : the official journal of the Italian Pharmacological Society 70: 102-115, 2013.
30. Sahoo SK and Labhasetwar V: Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2: 373-383, 2005.
31. Sneh-Edri H, Likhtenshtein D and Stepensky D: Intracellular targeting of PLGA nanoparticles encapsulating antigenic peptide to the endoplasmic reticulum of dendritic cells and its effect on antigen cross-presentation in vitro. Mol Pharm 8: 1266-1275, 2011.
32. Lesley J, Hascall VC, Tammi M and Hyman R: Hyaluronan binding by cell surface CD44. J Biol Chem 275: 26967-26975, 2000.
33. Song J-M, Im J-H, Kang J-H and Kang D-J: A simple method for hyaluronic acid quantification in culture broth. Carbohydrate Polymers 78: 633-634, 2009.
34. Underhill CB and Toole BP: Binding of hyaluronate to the surface of cultured cells. J Cell Biol 82: 475-484, 1979.
35. Zaki NM, Nasti A and Tirelli N: Nanocarriers for cytoplasmic delivery: cellular uptake and intracellular fate of chitosan and hyaluronic acid-coated chitosan nanoparticles in a phagocytic cell model. Macromol Biosci 11: 1747-1760, 2011.
36. Holzer M, Vogel V, Mantele W, Schwartz D, Haase W and Langer K: Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage. Eur J Pharm Biopharm 72: 428-437, 2009.